President of Lilly Oncology quits to take up CEO post at Savient
US drug major Eli Lilly (NYSE: LLY) announced yesterday that John Johnson, senior vice president and president of Lilly Oncology, has resigned effective January 28, 2011. A successor will be announced in the coming weeks.
The decision of Mr Johnson, who was previously chief executive of ImClone, which Lilly acquired in 2008, was was driven by personal and family considerations, according to a Lilly statement.
However, almost simultaneously, drug developer Savient Pharmaceuticals (Nasdaq: SVNT) revealed that it has named Mr Johnson as chief executive - a role that has been vacant since 2008 - effective January 31, 2011. He will also serve as a member of Savient's board of directors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze